Edgar Filing: Akebia Therapeutics, Inc. - Form 4

Akebia Thera	apeutics, Inc.										
Form 4											
May 28, 201	5										
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION								OMB APPROVAL			
	UNITED STATES SECURITIES AND EXCHANGE COMMISSION								OMB	3235-0287	
Check thi	is box		Was	shington	, D.C. 20	549			Number:	January 31,	
if no longer which to state st				CECIN	DENIEFI	CIAI		NEDSIIID OF	Expires:	2005	
subject to)		г спан			CIAI		NEKSHIP OF	Estimated average		
Section 1 Form 4 or		SECURITIES							burden hours per response 0.5		
Form 5		Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,								0.5	
obligation	ns Section	-					-	f 1935 or Section	n		
may cont See Instru	inue.		of the In	•	•						
1(b).	iction .				•	•					
(Print or Type F	Responses)										
1 1 1 4	11 (D	· ъ *						5 0 1 (* 1* 6			
Deetless Leless D				Name and	I Ticker or	Fradin	g	5. Relationship of Reporting Person(s) to Issuer			
Dutier John	1.		Symbol	Thoropou	tion Inc	LVI	5 A I				
				•	itics, Inc.		JAJ	(Chec	k all applicable	;)	
(Last)	(First)	(Middle)		Earliest T	ransaction			V D	100	0	
C/O AKEBI	(Month/D 05/26/20	-				_X_ Director 10% Owner _X_ Officer (give title Other (specify					
	IRST STREE		03/20/20	015				below)	below)		
1100		1,00111						CEC	and President		
	(Street)		1 If Ama	ndmant D	ata Original			6 Individual or Ia	int/Croun Filir	or (Chaola	
	(Sueet)			ith/Day/Yea	ate Original			6. Individual or Joint/Group Filing(Check Applicable Line)			
Theu				itil/Day/10a	()			_X_Form filed by One Reporting Person			
CAMBRID	GE, MA 0214	-2						Form filed by N Person	Iore than One Re	porting	
(City)	(State)	(Zip)	Tabl	e I - Non-I	Derivative	Securi	ties Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of	2. Transaction			3.	4. Securi		-	5. Amount of	6. Ownership		
Security (Instr. 3)	(Month/Day/Y		on Date, if	Transacti Code	on(A) or Di	-		Beneficially	· /	Indirect Beneficial	
(IIIsu. 3)		any (Month/	Day/Year)	(Instr. 8)	(Instr. 3,	+ anu .))			Ownership	
		((insu: 0)				Following	(Instr. 4)	(Instr. 4)	
						(A)		Reported			
						or		Transaction(s) (Instr. 3 and 4)			
C				Code V	Amount	(D)	Price	(mou. 5 and 4)			
Common	05/26/2015			М	50,000	А	\$	198,350	D		
Stock							0.47				

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, i any (Month/Day/Yea	Code	5. Number of iorDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		
Stock Option (Right to Buy)	\$ 0.47	05/26/2015		М	50,000	<u>(1)</u>	09/16/2023	Common Stock	50,000		
Reporting Owners											
Reporting Owner Name / Address				ationships							
			Director 10	% Owner 0	Officer	Othe	er				

Edgar Filing: Akebia Therapeutics, Inc. - Form 4

 Director
 10% Owner
 Officer
 O

 Butler John P.
 C/O AKEBIA THERAPEUTICS, INC.
 X
 CEO and President

 245 FIRST STREET, SUITE 1100
 X
 CEO and President

 CAMBRIDGE, MA 02142
 Signatures
 5

 Nicole R. Hadas, attorney-in-fact for John P.
 05/28/2015

 **Signature of Reporting Person
 Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This transaction represents the acquisition of common stock as a result of the exercise and hold of derivative securities reported in Table
 (1) II. This option was granted on September 16, 2013. Twenty-five percent vested on September 16, 2014 with the remaining seventy-five percent vesting in equal monthly installments thereafter until fully vested on September 1, 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.